Document is current
Any future updates will be listed below
-
Authors
Petruzzelli, Raffaella https://orcid.org/0000-0003-2868-4486
Catalano, Federico
Crispino, Roberta
Polishchuk, Elena V.
Elia, Mariantonietta
Masone, Antonio https://orcid.org/0000-0001-8357-5931
Lavigna, Giada
Grasso, Anna https://orcid.org/0009-0009-9192-5749
Battipaglia, Maria
Sepe, Lucia Vittoria
Akdogan, Banu
Reinold, Quirin
Del Prete, Eugenio https://orcid.org/0000-0003-3214-9021
Carrella, Diego
Torella, Annalaura
Nigro, Vincenzo
Caruso, Enrico https://orcid.org/0000-0002-6700-911X
Innocenti, Nicole https://orcid.org/0000-0002-3513-950X
Biasini, Emiliano https://orcid.org/0000-0002-3927-6341
Puchkova, Ludmila V. https://orcid.org/0000-0003-0958-2812
Indrieri, Alessia https://orcid.org/0000-0002-2325-0913
Ilyechova, Ekaterina Y.
Piccolo, Pasquale https://orcid.org/0000-0002-8614-2581
Zischka, Hans
Chiesa, Roberto https://orcid.org/0000-0002-3842-3733
Polishchuk, Roman S. https://orcid.org/0000-0002-7698-1955
-
Funding
Funding for this research was provided by:
Fondazione Telethon (TGM22CBDM05, GGP15225)
Russian Science Foundation (22-24-00762, 20-74-10087)
- License Information
-
More Information
Article History
Received: 15 May 2024
Accepted: 17 January 2025
First Online: 8 February 2025
Competing interests
: The authors disclose pending patent application priority filing (Applicant: Fondazione Telethon ETS, Inventor: RSP, Application #: IT 102024000028707) for the use of PrP as a target to treat disorders of copper metabolism and Wilson disease in particular. The specific aspect of manuscript covered in patent application includes the use of genetic and pharmacological suppression of PrP for reduction of copper toxicity.
